Evaluation of PrEP-30: a Demonstration Project of Pre-exposure Prophylaxis for MSM and Other High-risk Group Clients at the Thai Red Cross Anonymous Clinic

Thai Red Cross AIDS Research Centre (TRC-ARC)

Status

Enrolling by invitation

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT02437981

Acronym

PrEP-30

Enrollment

20000

Registered

2015-05-08

Start date

2014-12-31

Completion date

2027-01-31

Last updated

2024-11-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

HIV Prevention

Brief summary

PrEP-30 is a demonstration project to assess the feasibility of providing oral PrEP to MSM and other individuals at-risk for HIV in Bangkok, Thailand as a service that is funded entirely through user fees. Tenofovir disoproxil fumarate/emtricitabine PrEP is provided part of a combined HIV prevention program that includes risk-reduction counseling, regular HIV testing, and the provision of condoms and lubricants. PrEP-30 is implemented at the Thai Red Cross AIDS Research Centre, at the site of the largest HIV counseling and testing center in Thailand.

Interventions

DRUGPrEP

Oral pre-exposure prophylaxis (PrEP) for HIV infection using a daily combination tablet of tenofovir disoproxil fumarate and emtricitabine

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Yes

Inclusion criteria

1. Age \> 18 years 2. HIV test negative 3. Creatinine clearance \> 60 ml/min 4. No contraindication or allergy to PrEP medications (TDF/FTC) 5. At least one risk factor for HIV infection within the previous 6 months: * sex partner known to be HIV positive * works as commercial sex worker * use of PEP for sexual exposure * injection drug use * any STI (syphilis, gonorrhea, chlamydia) * \> 5 sex partners * inconsistent condom use with high-risk partners, including MSM, IDU * MSM: any insertive or receptive anal sex without condom * Women: any sex without condom with high-risk male partner (MSM, IDU, multiple female partners) * Heterosexual men: any sex without condom with high-risk female partner (commercial sex worker, IDU, multiple male partners)

Exclusion criteria

Design outcomes

Primary

Measure	Time frame	Description
Primary outcome measures:	12 months	1. Assess the uptake of fee-based oral PrEP by MSM and other at-risk individuals who present for HIV testing or other services. 2. Assess the acceptability, tolerance and safety of oral PrEP. 3. Assess patient satisfaction with oral PrEP delivered through a fee-based system in an HIV testing center. 4. Assess the effectiveness of oral PrEP in a fee-based model. 5. Assess the cost-effectiveness of oral PreP delivered in a fee-based system.

Countries

Thailand

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026